<div id="readability-page-1"><p>Harmony Biosciences <span>NASDAQ: HRMY<span></span></span> executives outlined 2026 priorities at Needham &amp; Company’s Virtual Healthcare Conference, emphasizing continued growth for WAKIX and multiple late-stage pipeline readouts across sleep-wake and rare epilepsy indications.</p><div><p><span></span><span>Get <strong>Harmony Biosciences</strong> alerts:</span></p></div><h2>WAKIX outlook and commercial execution</h2> <p>President and CEO Jeffrey Dayno said Harmony is “on track to achieve over $1 billion in net revenue for WAKIX in its sixth year on the market,” describing the product as the company’s foundation for near- and long-term growth. </p><p>Chief Commercial Officer Adam Zaeske pointed to accelerating patient growth exiting 2025. While the company “typically see[s] patient additions of 100-400 patients a quarter,” Zaeske said the last three quarters saw “400-500 patient adds,” which he characterized as “really, really strong growth and momentum carrying us into 2026.” He attributed the performance to WAKIX’s differentiation as “the only non-scheduled treatment option available for patients,” along with broad access and ongoing refinements to sales execution, payer coverage, and patient support processes intended to speed time to dispense. </p><p>Looking ahead, Zaeske said Harmony expanded its commercial organization in the first quarter, increasing field sales, remote sales, and field reimbursement teams “on average of about 20%,” with hires in place and trained.  </p><h2>ANDA litigation and loss-of-exclusivity planning</h2> <p>Fadia asked about an outstanding abbreviated new drug application (ANDA) filer. Dayno said Harmony has “settled with six of the seven ANDA filers” with loss of exclusivity (LOE) “to September of 2029,” and he added that pediatric exclusivity—“for which we’re on track to achieve”—would extend that to “March of 2030.” </p><p>On the ongoing trial process, Dayno said post-trial briefs were submitted the prior Thursday and the company cannot “predict the timing or the outcome.” He said Harmony remains focused both on completing settlement efforts and on advancing next-generation pitolisant programs.  </p><h2>Pitolisant franchise: GR and high-dose programs</h2> <p>Dayno highlighted multiple pitolisant lifecycle initiatives. He said pitolisant GR (gastroresistant) is “on track for NDA submission this quarter,” with a target PDUFA date in “the first quarter of next year of 2027.” </p><p>Zaeske said the GR formulation is intended to improve the patient experience, noting that “80% of patients with narcolepsy have the potential for GI symptoms related to the disease.” He said the GR coating “adds to” WAKIX’s tolerability foundation and also enables patients to “start at a therapeutic dose” with “no titration required.” Zaeske added that Harmony’s distribution model allows it to recontact prior WAKIX patients who consented at initiation, potentially informing patients who discontinued for various reasons that a GR formulation is available. He said Harmony has “historically…thought about the GR as between $3 million and $500 million opportunity.” </p><p>For pitolisant high dose (HD), Zaeske described the strategy as “a totally new branded launch and a highly differentiated product,” combining the GR benefits with “up to 2x the approved dose of WAKIX” and pursuing “unique indications in narcolepsy and IH.” He said the company is running two phase III registrational trials—one in narcolepsy and one in idiopathic hypersomnia (IH)—with “target PDUFA dates both in 2028,” and said Harmony has discussed HD as “a billion-plus opportunity.” </p><p>Dayno added that HD is “a unique formulation” with “a different PK profile,” stating that “milligram for milligram, greater exposure” has been demonstrated, with safety margins “well beyond going two times the highest labeled dose.” He also said the GR and HD programs are designed to support potential new labeling in areas such as “fatigue in narcolepsy” and “sleep inertia in IH,” and that the company has “utility patents out through 2044” for both GR and HD.  </p><h2>New pitolisant formulation targeting fatigue</h2> <p>Dayno and Chief Medical and Scientific Officer Kumar Budur discussed an additional pitolisant formulation obtained via an exclusive license backed by an issued patent “until 2042.” Budur said Harmony’s interest in fatigue stems from its “multidimensional” nature—emotional, physical, and cognitive—and argued the histaminergic mechanism, including downstream norepinephrine and serotonin effects, is “uniquely positioned to address all three aspects of fatigue.” </p><p>Budur cited Harmony’s phase II proof-of-concept study in type 1 myotonic dystrophy, where about 90% of patients have significant fatigue, saying pitolisant improved fatigue “in a clinically meaningful way” and showed a “dose response.” He also noted pitolisant is labeled in Europe for residual excessive daytime sleepiness in obstructive sleep apnea. Based on characteristics of the newly licensed formulation, Budur said Harmony prioritized fatigue in multiple sclerosis because fatigue is “very well characterized” in MS and affects a large proportion of patients. He said the company is “optimizing the formulation” and expects the next step to be a phase I pharmacokinetic study.  </p><h2>Orexin program and EPX-100 in rare epilepsies</h2> <p>Management also addressed the evolving orexin landscape and Harmony’s own orexin receptor agonist, BP1.15205. Zaeske said physicians show interest in orexins based on efficacy but still have questions about tolerability and longer-term data, citing reported adverse events such as “pretty high rates of insomnia,” frequent urination, and visual disturbances. He said Harmony expects a “gradual approach” to adoption and argued that new brands in narcolepsy historically expand branded utilization rather than solely shift share, reflecting a polypharmacy treatment paradigm. Zaeske said WAKIX’s “exceptional safety and tolerability” and “extremely clean profile” support its role as an add-on therapy. </p><p>Budur said BP1.15205 is “the most potent orexin receptor agonist in clinical development,” describing potency at “0.015 nanomolar levels,” a novel chemical scaffold intended to avoid off-target issues seen with earlier compounds, and a preclinical profile supportive of “potentially once-a-day dosing.” Dayno said Harmony expects top-line data from a phase I single-ascending-dose PK study in healthy volunteers “mid-year,” followed by an IND submission “mid-year” and a sleep-deprived healthy volunteer study to evaluate safety, tolerability, dose-ranging, and initial signals of efficacy. </p><p>In rare epilepsy, Budur discussed EPX-100, referencing open-label ARGUS data presented at AES showing a “50% median reduction” in CMS-28 from baseline. He emphasized EPX-100 is being developed as adjunctive therapy on top of multiple anti-epileptic drugs and said the program’s differentiation could include tolerability and safety, citing low rates of clinically relevant GI adverse events and no expected need for special routine monitoring such as LFT checks or echocardiograms required with other therapies. Dayno reiterated two phase III trials are advancing in Dravet syndrome and Lennox-Gastaut syndrome, with top-line data anticipated in 2027 and target PDUFA dates in 2028.  </p><p>Dayno also highlighted business development as a key priority, citing “over $880 million on our balance sheet.” He said Harmony’s focus remains orphan and rare CNS and neuropsychiatric targets, but the company has “opened up the aperture” to consider broader indications adjacent to its sleep-wake and rare epilepsy franchises, including potentially “on market” assets and opportunities ranging from smaller tuck-ins to more transformational deals.</p><h2>About Harmony Biosciences <span>NASDAQ: HRMY<span></span></span></h2><p>Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company's mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.  </p><p>The company's flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.</p><h2>See Also</h2><ul><li>Five stocks we like better than Harmony Biosciences</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Harmony Biosciences Right Now?</h2><p>Before you consider Harmony Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.</p><p>While Harmony Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HRMY

<p>Harmony Biosciences executives presented their 2026 priorities at the Needham & Company Virtual Healthcare Conference, highlighting a projected $1 billion in net revenue for WAKIX. The company reported strong patient growth and plans to expand its commercial organization. They have settled with six of seven ANDA filers, extending exclusivity to 2030. Upcoming initiatives include a gastroresistant formulation and a high-dose pitolisant, both targeting narcolepsy and idiopathic hypersomnia, with potential billion-dollar opportunities. Additionally, a new formulation targeting fatigue in multiple sclerosis is in development, with a phase I study expected soon.</p>

Harmony Biosciences Eyes $1B WAKIX Runway, Teases 2026 Pipeline Catalysts at Needham Conference